Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
AMES, Iowa , Nov. 14, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Eugene P. Kennedy , M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all clinical development, medical affairs and related functions. Dr.
View HTML
Toggle Summary NewLink Genetics to Participate in November Investor Conferences
AMES, Iowa , Nov. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) will participate in the following investor conferences this week: Stifel 2017 Healthcare Conference on Tuesday, November 14 th , at 5:00pm ET in New York City Jefferies 2017 London Healthcare Conference
View HTML
Toggle Summary NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program
- Management to Host Conference Call Today at 8:30 a.m. ET
View HTML
Toggle Summary NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod 
AMES, Iowa , Oct. 30, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that indoximod, its leading drug development candidate, was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Stage IIb-IV
View HTML
Toggle Summary NewLink Genetics to Host Its Third Quarter 2017 Financial Results Conference Call on November 2, 2017
AMES, Iowa , Oct. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today announced that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and
View HTML
Toggle Summary NewLink Genetics Prices Public Offering of Common Stock
AMES, Iowa , Oct. 03, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (" NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $10.25 per
View HTML
Toggle Summary NewLink Genetics Announces Proposed Public Offering of Common Stock
AMES, Iowa --(BUSINESS WIRE)-- NewLink Genetics Corporation (" NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $50,000,000 of shares of its common stock in an underwritten public
View HTML
Toggle Summary NewLink Genetics Announces Clinical Collaboration to Evaluate IO-Based Combination Therapies in Pancreatic Cancer
Phase 2, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, an immune checkpoint inhibitor, along with gemcitabine/ABRAXANE ® (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE ® versus gemcitabine/ABRAXANE ® AMES, Iowa --(BUSINESS WIRE)-- NewLink
View HTML
Toggle Summary Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
Pivotal Trial of Indoximod in Advanced Melanoma to Include Both PD-1 Inhibitors, KEYTRUDA (pembrolizumab) and OPDIVO ® (nivolumab) AMES, Iowa --(BUSINESS WIRE)-- NewLink Genetics Corporation (NASDAQ: NLNK) today announced updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conferences
AMES, Iowa , Aug. 29, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September: Baird Global Healthcare Conference on September 7 at 1:25pm ET in New York City Cantor Fitzgerald Global Healthcare
View HTML